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INTRODUCTION: 
Nanosuspensions are colloidal dispersions and biphasic 
system consisting of drug particles dispersed in an aqueous 
vehicle in which the diameter of the suspended particle is 
less than 1μm in size. Reduction of drug particles to 
nanometer range leads to an enhanced dissolution rate due to 
increased surface area and saturation solubility
1
. 
 
Figure 1: Nanosuspension applications in the field of 
medicine 
Nanosuspensions have revealed their potential to tackle the 
problems associated with the delivery of poorly water-
soluble and poorly water-and lipid-soluble drugs, and are 
unique because of their simplicity and the advantages they 
confer over other strategies. This review focuses on the 
various aspects of nanosuspensions and their potentials as 
promising strategy in drug delivery. Nanotechnology is 
defined as the science and engineering carried out in the 
nanoscale that is 10-9 meters
 2
. 
 Nanotechnology is an applicable aspect of a broader area of 
nano science which is one of the upcoming and highly 
challenging as well as rewarding key research area in the 
modern scientific set up. It is the science of small particle 
having unique properties, which change on altering the size 
of the particle
3
. 
 Pharmaceutical industries are constantly seeking new 
approaches in order to obtain an adequate oral 
bioavailability, as most of biological properties exhibiting 
NCEs are poorly water - soluble. The increasing frequency of 
poorly water soluble NCEs exhibiting therapeutic activity is 
of major concern to the development of new formulations in 
pharmaceutical industry which leads to low turnout in the 
development of new molecular entities as drug formulations 
is poor solubility and poor permeability of the lead  
compounds. Recently, the formulation of such drugs as 
nanoscale systems (which have a size below 1μm) has 
rapidly evolved as a new and novel drug delivery system. 
The major characteristic of these systems is the rapid 
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dissolution rate, which enhance bioavailability after oral 
administration
4
. 
TECHNIQUE OF PREPARATION OF 
NANOSUSPENSION 
Mainly there are two methods for preparation of 
nanosuspensions. The conventional methods of precipitation 
(Hydrosols) are called „Bottom up technology‟. In Bottom up 
Technology the drug is dissolved in a solvent, which is then 
added to non-solvent to precipitate the crystals. This 
technique is that during the precipitation procedure the 
growing of the drug crystals needs to be controlled by 
addition of surfactant to avoid formation of 
microparticles
5
.The „Top Down Technologies‟ include 
Media Milling (Nanocrystals), High Pressure  
Homogenization in water (Dissocubes), High Pressure 
Homogenization in non aqueous media (Nanopure) and 
combination of Precipitation and High-Pressure 
Homogenization (Nanoedege)
6,7
. 
Improvement of bioavailability 
Improvement of bioavailability of poorly water soluble drug 
remains one of the most challenging aspects of drug 
development. By many estimates up to 40% of new chemical 
entities discovered by the pharmaceutical industry today are 
poorly water soluble compounds. Consideration of the 
modified Noyes-Whitney equation provides some hints as to 
how the dissolution rate of even very poorly soluble 
compounds might be improved tominimize the limitations to 
oral availability
8
. The main possibilities for improving 
dissolution according to thisanalysis are: 
• To increase the surface area available for dissolution by 
decreasing the particle size of the solid compound: 
• By optimizing the wetting characteristics of the compound 
surface, 
• To decrease the diffusion layer thickness, 
• To ensure sink conditions for dissolution and, 
• To improve the apparent solubility of the drug under 
physiologically relevant conditions
9
. 
Need of Nanosuspension for bioavailability enhancement 
Nevertheless, pharmacokinetic studies of BCS class – II 
drugs showed that they have a low oral bioavailability, which 
may be due to poor water solubility of drug. There are many 
classical pharmaceutical ways to improve drug dissolution 
rate such as dissolution in aqueous mixtures with an organic 
solvent
10
; formation of ß-cyclodextrincomplexes
11
; solid 
dispersions
12
; and drug salt form
13
. 
ADVANTAGES OF NANOSUSPENSIONS 
The major advantages of nanosuspension technology are
14
: 
• Provides ease of manufacture and scale-up for large scale 
production 
• Long-term physical stability due to the presence of 
stabilizers 
• Oral administration of nanosuspensions provide rapid 
onset, reduced fed/fasted ratio and improved bioavailability 
• Rapid dissolution and tissue targeting can be achieved by 
IV route of administration. 
Interesting special features of nanosuspensions  
• Increase in saturation solubility and consequently an 
increase in the dissolution rate of the drug. 
• Increase in adhesive nature, thus resulting in enhanced 
bioavailability
15
. 
Criteria for selection of drug for nanosuspensions 
Nanosuspension can be prepared for the API that is having 
either of the following characteristics
16
. Water insoluble but 
which are soluble in oil (high log P) or API are insoluble in 
both water and oils Drugs with reduced tendency of the 
crystal to dissolve, regardless of the solvent API with very 
large dose. 
CHARACTERIZATION TECHNIQUES: 
Nanosuspensions are characterized for appearance, color, 
ordor, assay, related impurities, particle size, zeta potential, 
crystalline status, dissolution studies and in vivo studies. 
Among this, the most important characterization techniques 
were discussed. 
1. Mean particle size and particle size distribution 
The mean particle size and the span of particle size 
distribution (polydispersity index, PI) are two important 
characteristic parameters because they affect the saturation 
solubility, dissolution rate, physical stability, even in-vivo 
behavior of nanosuspensions
17
. 
2. Surface charge (zeta potential) 
Zeta potential gives certain information about the surface 
charge properties and further the long-term physical stability 
of the nanosuspensions. The zeta potential of a 
nanosuspension is governed by both the stabilizer and the 
drug itself
18
. 
3. Crystalline state and particle morphology 
The assessment of the crystalline state and particle 
morphology togather helps in understanding the polymorphic 
or morphological changes that a drug might undergo when 
subjected to nanosizing
17
. Nanosuspensions can undergo a 
change in the crystalline structure, which may be to an 
amorphous form or to other polymorphic forms because of 
high pressurehomogenization
19
. 
4. Saturation solubility and dissolution velocity 
Nanosuspensions have an important advantage over other 
techniques, that it can increase the dissolution velocity as 
well as the saturation solubility. The saturationsolubility of 
the drug in different physiological buffers as well as at 
different temperatures should be assessed using methods 
described in the literature. 
FORMULATION OF NANOSUSPENSION 
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1. Stabilizer 
Stabilizer plays an important role in the formulation of 
nanosuspensions. In the absence of an appropriate stabilizer, 
the high surface energy of nano-sized particles can induce 
agglomeration or aggregation of the drug crystals. The main 
functions of a stabilizer are to wet the drug particles 
thoroughly, and to prevent Ostwald‟s ripening and 
agglomeration of nanosuspensions in order to yield a 
physically stable formulation by providing stericor ionic 
barriers. The type and amount of stabilizer has a pronounced 
effect on the physical stability and in-vivo behavior of 
nanosuspensions. In some cases, a mixture of stabilizers is 
required to obtain a stable Nanosuspension. 
2. Organic solvents 
Organic solvents may be required in the formulation of 
nanosuspensions if they are to be prepared using an emulsion 
or microemulsion as a template. As these techniques are still 
in their infancy, elaborate information on formulation 
considerations is not available. The acceptability of the 
organic solvents in the pharmaceutical area, their toxicity 
potential and the ease of their removal from the formulation 
need to be considered when formulating a nano suspensions 
using emulsions or microemulsions as templates. 
3. Co-surfactants 
The choice of co-surfactant is critical when using 
microemulsions formulate nanosuspensions. Since co-
surfactant scan greatly influence phase behavior, the effect of 
co-surfactant on uptake of the internal phase for selected 
microemulsions composition and on drug loading should be 
investigated. Although the literature describes the use of bile 
salts and dipotassiumglycerrhizinate as co-surfactants, 
various solubilizers, such as Transcutol, glycofurol, ethanol 
and isopropanol, can be safely used as co-surfactants in the 
formulation of microemulsions
20,21
. 
4. Other additives 
Formulation considerations Nanosuspensions may contain 
additives such as buffers, salts, polyols, osmogentand 
cryoprotectant, depending on either the route of 
administration or the properties of the drug moiety
22
. 
4.1. In-vitro evaluations 
4.1.1. Particle size and size distribution 
4.1.2. Particle charge (Zeta Potential) 
4.1.3. Crystalline state and morphology 
4.1.4. Saturation solubility and dissolution velocity
23
. 
4.2. In-vivo evaluation 
4.3. Evaluation for surface-modifirdnanosuspension 
4.3.1. Surface hydrophilicity 
4.3.2. Adhesion properties 
4.3.3. Interaction with body proteins. 
4.1. In-vitro evaluation: 
4.1.1. Mean particle size and size distribution 
The mean particle size and the width of particle size 
distribution (called Polydidpersity Index) are determined by 
Photon Correlation Spectroscopy (PCS). Particle size and 
polydispersity index (PI) governs the saturation solubility; 
dissolution velocity and biological performance. It is proved 
that change in particle size changes saturation solubility and 
dissolution velocity. PCS measures the particle size in the 
range of 3 nm- 3 μm only. PCS is a versatile technique but 
has low measuring range. In addition to PCS analysis 
nanosuspensions are analyzed by Laser Diffractometry (LD). 
4.1.2. Particle charge (zeta potential) 
The determination of the zeta potential of a nanosuspension 
is essential as it gives an idea about the potential of a 
nanosuspension is governed by both the stabilizer and the 
drug itself. In order to obtain a nanosuspensions exhibiting 
good stability, for an electrostatically stabilized 
nanosuspensions minimum zeta potential of 30mV is 
required whereas in the case of a combined electrostatic and 
20 mV is desirable. 
4.1.3. Crystalline state and particle morphology 
The X-Ray Diffraction (XRD) is also used for determining 
change in physical state and extent of amorphous drug. 
Differential Scanning Calorimetry (DSC) determines the 
crystalline structure. When nanosuspensions are prepared 
drug particles get converted to amorphous form hence it is 
essential to measure the extent of amorphous drug generated 
during the production of nanosuspensions. See table 1.
Table 1: Current Marketed Pharmaceutical Products Utilizing Nano crystalline Formulation: 
Product  Drug  
Compound  
Indication  Company  Nanoparticle  
technology  
RAPAMUNE®  Sirolimus Immunosuppressant  Wyeth  Elan Drug Delivery Na-nanocrystals 
EMEND®  Aprepitant Antiemetic  Merck  Elan Drug Delivery  
Nanocrystals®  
TriCor®  Fenofibrate Hypocholesteremic Abbott  Elan Drug Delivery  
Nanocrystals®  
MEGACE® ES  Megestrol 
Acetate  
Appetite stimulant  PAR 
Pharmaceutical  
Elan Drug Delivery  
Nanocrystals®  
Triglide™  Fenofibrate Hypocholesteremic First Horizon 
Pharmaceutical 
SkyePharmaIDD®-P technology  
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4.1.4. Solubility and Dissolution velocity 
The main advantage associated with then a nosuspensions is 
improved saturation Solubility as well as dissolution 
velocity. These are studied in different physiological solution 
sat different pH. Kelvin equation and the Ostwald-Freundlich 
equations can explain increase in saturation solubility. 
Determination of these parameters is useful to assess in vivo 
performance of theformulation. 
4.2. In-vivo evaluation 
The in vivo evaluation of the nanosuspensions is specific to 
drug and route of administration. Most commonly the 
formulation was given by required route of administration 
and the plasma drug levels were estimated using HPLC-UV 
visible Spectrophotometry. 
Applications 
Applications of nanosuspensions had land marking history 
and the applications given are few. 
1. Oral drug delivery  
The oral route is the preferred route for drug delivery 
because of its numerous well-known advantages. .Orally 
administered antibiotics such as atovaquone and 
bupravaquone reflect this problem very well. Nanosizing of 
such drugs can lead to a dramatic increase in their oral 
absorption and subsequently bioavailability
24
. 
2. Parenteral drug delivery  
One of the important applications of nanosuspension 
technology is the formulationof intravenously administered 
products. IV administration results in several 
advantages,such as administration of poorly soluble drugs 
without using a higher concentration of toxicco-solvents, 
improving the therapeutic effect of the drug available as 
conventional oralformulations and targeting the drug to 
macrophages nanosuspensions of poorly soluble drug 
tarazepide have been prepared to overcome the limited 
success achieved using conventional solubilization 
techniques, such as use of surfactants, cyclodextrins, etc., to 
improve bioavailability
25
. 
3. Pulmonary drug delivery 
Nanosuspensions may prove to be an ideal approach for 
delivering drugs that exhibitpoor solubility in pulmonary 
secretions. Aqueous nanosuspensions can benebulized using 
mechanical or ultrasonic nebulizers for lung delivery. 
Because oftheir small size, it is likely that in each aerosol 
droplet at least one drug particle iscontained, leading to a 
more uniform distribution of the drug in lungs
26
. The 
nanoparticulate nature of the drug allows the rapid diffusion 
and dissolution of the drug at the site of action. 
4. Ocular drug delivery 
Nanosuspensions can prove to be a boon for drugs that 
exhibit poor solubility inlachrymal fluids. Nanosuspensions, 
by their inherent ability to improve the saturationsolubility of 
the drug, represent an ideal approach for ocular delivery of 
hydrophobic drugs and Nanoparticulate nature of the drug 
allows its prolonged residence in the culdesac, giving 
sustained release of the drug
24
. 
5. Targeted drug delivery 
Nanosuspensions can be used for targeted delivery as their 
surface properties and in-vivobehavior can easily be altered 
by changing either the stabilizer or the milieu. The 
engineering of stealth nanosuspensions (analogous to stealth 
liposomes) by using various surface coatings for active or 
passive targeting of the desired site is the future of targeted 
drug delivery systems
27
. 
6. Mucoadhesion of the nanoprticles 
Nanoparticles orally administered in the form of a 
suspension diffuse into the liquidmedia and rapidly 
encounter the mucosal surface. The direct contact of the 
particles with the intestinal cells through a bioadhesive phase 
is the first step before particle absorption
28
. See table 2. 
 
Table 2: The New Drug Application Based on Nanosuspensions Technique Reported and Marketed by Now: 
Drugs  Indication  Author or Company  Route  Status  
Paclitaxel  Anticancer  American Bioscience  Intravenous  Marketed  
Danazol Hormone  Rogers T.L.  Oral  Reported  
Naproxen  Anti-inflammatory  AnchaleeAin-Ai  Oral/parenteral  Reported  
Probucol Lipid lowering  JyutaroShudo Oral  Reported  
Rapamune Immunosuppressant  ElanNanosystems Oral  Marketed  
Emend  Anti-emetic  ElanNanosystems Oral  Marketed  
Cytokine inhibitor  Crohn‟s disease  ElanNanosystems Oral  Phase II  
Fenofibrate Lipid lowering  SkyePharma Oral  Marketed  
Megestrol acetate  Steroid hormone  Par Pharmaceuticals  Oral  Marketed  
Paliperidone pal-mitate Anti-schizophrenia  Johnson and Johnson  Oral  Phase III  
Loviride Antivirotic B. Van Eerdenbrugh Intravenous  Reported  
Busulfan Anticancer  Skye Pharma Intrathecal Undisclosed  
Budesonide  Asthma  Jerry Z. Yang  Pulmonary  Reported  
Fluticasone  Asthma  Jerry Z. Yang  Pulmonary  Reported  
Insulin  Diabetes  BioSante Oral  Undisclosed  
Clofazimine Antimycobacterials K. Peters  Intravenous  Reported  
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Buparvaquone Antibiotic  Müller R. H.  Oral  Reported  
Oridonin Anticancer  Lei Gao Intravenous  Reported  
AZ68  Anticancer  Kalle S.  Oral/I.V.  Reported  
Ascorbylpalmitate Ascorbylpalmitate Veerawat T.  Intravenous  Reported  
Hydrocortisone  Glucocorticoid  M.A. Kassem Ophthalmic  Reported  
Prednisolone  Glucocorticoid  M.A. Kassem Ophthalmic  Reported  
Hexadecadrol Glucocorticoid  M.A. Kassem Ophthalmic  Reported  
Aphidicolin Antileishmanial O. Kayser Oral  Reported  
Dihydroartemisinin Antimalarial  Jiraporn C.  Intravenous  Reported  
Cilostazol Antiplatelet agent  Jun-ichiJinno Oral  Reported  
Carbamazepine  Psychotolytic D. Douroumis Oral  Reported  
Omeprazol Proton pump inhibitor  Jan Möschwitzer Intravenous  Reported  
Thymectacin Anticancer  Elan Nanosystems Intravenous  Undisclosed  
Silver  Eczema  NUCRYST  Topical  Phase III  
Mitotane Adrenal Cortex Hormones  Michele Trotta Oral  Reported  
Griseofulvin Antifungal  Boris Y. Shekunov Oral  Reported  
Tarazepide Selective CCKa-antagonist  C. Jacobs  Oral  Reported  
Albendazole Anthelmintic drug  Mittapalli P. K.  Oral  Reported  
Azithromycin  Antimicrobial  Dianrui Zhang  Oral  Reported  
Ketoprofen Analgesic  Remon J.P.  Oral  Reported  
 
 
CONCLUSION 
Nanosuspensions are administering poorly water soluble 
drugs have been largely solved the dissolution problems to 
improve drug absorption and bioavailability. 
Nanosuspension technology can be combined with 
traditional dosage forms: tablets, capsules, pellets, and can be 
used for parenteral products.Drugs with poor solubility and 
low bioavailability are called „brick dust‟ candidates once 
abandoned from formulation development work can be 
rescued with nanosuspensions technology. A nanosuspension 
not only solve the problems of poor solubility and 
bioavailability but also alters the pharmacokinetics of drug 
and thus improves drug safety and efficacy.To take 
advantage of nanosuspension drug delivery, simple 
formation technologies and variety applications, 
nanosuspensions will continue to be of interest as oral 
formulations and non-oral administration develop in the 
future. Production techniques such as media milling and 
high-pressure homogenization have been successfully 
employed for large-scale production of nanosuspensions. The 
advances in production methodologies using emulsions or 
microemulsions as templates have provided still simpler 
approaches for production but with limitations. Further 
investigation in this regard is still essential. Attractive 
features, such as increased dissolution velocity, increased 
saturation solubility, improved bioadhesivity, versatility in 
surface modification and ease of post-production processing, 
have widened the applications of nanosuspensions for 
various routes. Nanosuspension solved poor bioavailability 
problem of hydrophobic drugs and drugs which are poorly 
soluble in aqueous and organic solutions. Productions 
techniques such as media milling and high pressure 
homogenizer are used for large scale production of 
nanosuspensions. Nanosuspensions can be administered 
through oral, parenteral, pulmonary, ocular and topical 
routes. Since nanotechnique is simple, less requirements of 
excipients, increased dissolution velocity and saturation 
solubility many poor bioavailability drugs are formulated in 
nanosuspension form. 
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